Immatics is a pioneering brand that combines the discovery of true targets for cancer immunotherapies with the development of specific T cell receptors. Their aim is to enable a robust T cell response against these targets. With over 400 team members across global sites in Germany and Texas, Immatics is committed to delivering the power of T cells and unlocking new avenues for patients in their fight against cancer.

Their pipeline includes Adoptive Cell Therapies and TCR Bispecifics, and they have partnerships with global leaders in the pharmaceutical industry. Immatics utilizes cutting-edge technology platforms for target and TCR discovery, and they have identified over 200 targets across major solid tumors. By identifying and characterizing novel intracellular tumor targets, Immatics has a distinct advantage in the drug discovery process.

They are dedicated to making a difference for patients and achieving better outcomes in the battle against cancer